Back to top
more

Addus HomeCare (ADUS)

(Delayed Data from NSDQ)

$126.27 USD

126.27
146,545

+1.85 (1.49%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $126.18 -0.09 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ADUS vs. USPH: Which Stock Is the Better Value Option?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Medtronic's (MDT) Global Market Share Strong, FX Headwind Stays

by Zacks Equity Research

Within cardiac rhythm management, Medtronic's (MDT) pacing business continues to outperform the market, banking on strong global growth of its Micra leadless pacemaker family.

LabCorp (LH) Expands Laboratory Relationship With New Pact

by Zacks Equity Research

LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.

HCA Healthcare (HCA) Gains 29% in a Year: More Upside Left?

by Zacks Equity Research

HCA Healthcare (HCA) is well-poised for growth on the back of higher revenues, a diversified treatment network and sound operating cash flows.

Here's Why You Should Hold Molina (MOH) in Your Portfolio

by Zacks Equity Research

Molina's (MOH) inorganic growth activities, financial flexibility and well-performing Medicaid and Medicare segments poise it for growth.

Is Addus HomeCare (ADUS) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Aparajita Dutta headshot

Bet on These 5 Low Leverage Stocks to Avoid Market Woes

by Aparajita Dutta

The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You may buy ELF, HST, ALK, ADUS & INSW

Here's Why Addus HomeCare (ADUS) is Poised for a Turnaround After Losing -24.6% in 4 Weeks

by Zacks Equity Research

Addus HomeCare (ADUS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Addus HomeCare (ADUS) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 7.78% and 1.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ADUS vs. USPH: Which Stock Is the Better Value Option?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Option Care (OPCH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Option Care (OPCH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 3.55% and 5.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Philips (PHG) Drives Healthcare Prospects With Enhanced Dataset

by Zacks Equity Research

Philips (PHG) announces its expansion with MIT IMES, which will help researchers and educators access a new critical care dataset.

ADUS or USPH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Are Medical Stocks Lagging Humana (HUM) This Year?

by Zacks Equity Research

Here is how Humana (HUM) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

Philips (PHG) Inks 7-Year Partnership With Northwell Health

by Zacks Equity Research

Philips (PHG) announces that it has entered into a seven-year agreement with Northwell Health, one of the largest healthcare providers in the state of New York.

Philips (PHG) Drives Health Care Prospects With New Solutions

by Zacks Equity Research

Philips (PHG) announces Philips Virtual Care Management solutions, which provide a comprehensive approach to telehealth for patients, providers and payers.

Is Addus HomeCare (ADUS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Addus HomeCare (ADUS) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Zacks Industry Outlook Highlights Chemed, Addus HomeCare, RadNet and The Pennant Group

by Zacks Equity Research

Chemed, Addus HomeCare, RadNet and The Pennant Group are part of the Zacks Industry Outlook article.

Here's Why You Should Retain HCA Healthcare (HCA) Stock Now

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and sufficient cash-generating abilities.

Debanjana Dey headshot

4 Promising Stocks From a Challenging Outpatient Home Health Industry

by Debanjana Dey

Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. CHE, ADUS, RDNT and PNTG are well poised to gain from the prospects.

ADUS or USPH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Is Addus HomeCare (ADUS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Addus HomeCare (ADUS) and Alcon (ALC) have performed compared to their sector so far this year.